

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Draper *et al.* CONFIRMATION NO.: 9127  
APPLICATION NO.: 10/692,563 EXAMINER: Sabiha Naim Qazi  
FILING DATE: October 24, 2003 ART UNIT: 1612  
FOR: SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA

**VIA EFS****SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

Applicants have not submitted copies of each cited U.S. patent and U.S. patent applications in accordance with 37 C.F.R. §1.98(a)(2)(ii). Applicants submit herewith copies of foreign patent documents (*i.e.*, B1 and B2) in accordance with 37 C.F.R. §1.98(a)(2).

Applicants also bring to the Examiner's attention co-pending U.S. Application No. 12/423,718, filed on 4/14/2009 (Attorney Docket No. 16534-564001US).

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the


APPLICANTS: Draper et al.  
U.S.S.N.: 10/692,563

information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 16534-526002US.

Respectfully submitted,



Heidi A. Erlacher, Reg. No. 45,409  
Christopher E. Olson, Reg. No. 55,510  
Attorney for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.

Address all written correspondence to

**Customer no.: 30623**

Tel: (617) 542-6000

Fax: (617) 542-2241

ACTIVE 4640796v.1